SAB Biotherapeutics (SABS) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SABS shares.
View SABS analyst ratings or view top-rated stocks.

1 analysts have issued twelve-month price objectives for SAB Biotherapeutics' shares. Their SABS share price forecasts range from $2.00 to $2.00. On average, they expect the company's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 198.5% from the stock's current price.
View analysts price targets for SABS or view top-rated stocks among Wall Street analysts.

SAB Biotherapeutics' stock was trading at $0.5899 at the beginning of the year. Since then, SABS shares have increased by 13.6% and is now trading at $0.67.
View the best growth stocks for 2023 here.

SAB Biotherapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 306,500 shares, a decrease of 17.5% from the August 31st total of 371,600 shares. Based on an average daily volume of 35,900 shares, the short-interest ratio is presently 8.5 days. Approximately 0.8% of the shares of the company are short sold.
View SAB Biotherapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023.
View our SABS earnings forecast.

SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its earnings results on Monday, August, 21st. The company reported ($0.14) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.14). The firm earned $0.09 million during the quarter. SAB Biotherapeutics had a negative trailing twelve-month return on equity of 110.34% and a negative net margin of 454.82%.

SAB Biotherapeutics trades on the NASDAQ under the ticker symbol "SABS."

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SABS stock can currently be purchased for approximately $0.67.

SAB Biotherapeutics (NASDAQ:SABS) has a market capitalization of $35.05 million and generates $23.90 million in revenue each year.

SAB Biotherapeutics' mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The official website for the company is www.bigcypressaccorp.com. The company can be reached via phone at 605-679-6980 or via email at ir@bigcypressaccorp.com.